For the latter, an effective action in cancer clinical trials is not expected, as this immunosuppressive drug impairs the tissue infiltration and activation of cytotoxic CD8+ T and CD4+ cells, which are the most relevant cells involved in the immune response to tumors. The gene discussed is CD4; the disease is cancer.